Thirteen studies were included in this review of medication related osteonecrosis of the jaw. The majority were case series ( 9) with the risk of osteonecrosis after tooth extraction being higher in those taking IV bisphosphonates ( 3.2% (95% CI: 1.7–4.7%) than those on oral bisphosphonates 0.15% (95% CI: 0.0–0.36%).
[read the full story...]
97 papers describing 4879 cases of bisphosphonate-related osteonecrosis were included in this review. A wide range of management approaches were identified but the quality of the available evidence is limited.
[read the full story...]
Bisphosphonates (BPs) are used for the treatment of a range of bone problems, e.g., osteoporosis, or bone metastases of malignant cancer. In 2003 the condition of bisphosphonate related osteonecrosis of the jaw (BONJ) was reported. The aim of this retrospective cohort study was to estimate the cumulative incidence and risk ratio for ONJ (osteonecrosis of [read the full story…]
